Needham analyst Michael Matson (NYSE:MATX) maintained a Buy rating on Zimmer Biomet Holdings (NYSE:ZBH) on Wednesday, setting a price target of $189, which is approximately 22.99% above the present share price of $153.67.
Matson expects Zimmer Biomet Holdings to post earnings per share (EPS) of $1.17 for the first quarter of 2021.
The current consensus among 20 TipRanks analysts is for a Strong Buy rating of shares in Zimmer Biomet Holdings, with an average price target of $170.74.
The analysts price targets range from a high of $193 to a low of $106.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.93 billion and a net profit of $324.5 million. The company's market cap is $31.85 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.5% and a 67.53% success rate.
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.